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Dear Editor,
We present the case of a 40-year old male patient 
with lymphomatoid papulosis of a waxing and wan-
ing course on whom three biopsies were performed 
during a 14-year period with no change in histopath-
ological or immunophenotypical characteristics. 
Lymphomatoid papulosis (LP) is a chronic, recur-
rent, self-healing papulonodular skin eruption with 
the histopathologic features of a cutaneous T-cell 
lymphoma but an often benign and indolent clinical 
course (1). It is designated as a primary, cutaneous, 
CD30+ lymphoproliferative disorder. The histopatho-
logic features of LP are variable, with five main types 
(A-E) and several other variants (2). In most cases, 
LP presents with a generalized eruption of reddish-
brown papules or nodules usually smaller than one 
cm on the trunk and limbs. Rarely, large, rapidly grow-
ing nodules may be the first manifestation of the dis-
ease (3). Patients with LP have an excellent prognosis 
even though they are at increased risk of develop-
ing secondary cutaneous or nodal lymphomas such 
as mycosis fungoides, primary cutaneous anaplas-
tic large cell lymphoma (PC-ALCL), or Hodgkin lym-
phoma (4). LP-associated lymphomas develop in be-
tween 10% and, as recently reported, 52% percent of 
patients and may occur before, concurrent with, or 
after the onset of LP (4,5).
Figure 1. Recent exacerbation of the disease. (a) Multiple papules and small nodules on the eyelids and face. (b) Clustered 
erythematosus papules and nodules, partially necrotic and ulcerated with scarring and post-inflammatory hyperpigmenta-
tion. (c) Tumor on the abdomen with smaller satellite papules, mimicking the clinical picture of primary cutaneous anaplastic 
large cell lymphoma (PC-ALCL).
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Our patient was diagnosed with “conventional” 
type An LP 14 years earlier based on the clinicopatho-
logic correlation. The diagnosis was confirmed a year 
later after excision of a rapid growing ulcerated nod-
ule on the forearm measuring 17 mm in diameter, 
which was clinically suspected to be anaplastic large 
cell lymphoma. During these 14 years, there were only 
a few worrisome recurrences of the disease, which re-
solved spontaneously or were successfully controlled 
with local steroids. During a recent exacerbation, 
when the third biopsy was performed, the patient 
presented with a large number of generalized red-
dish-brown pruritic papules and nodules on the trunk, 
extremities, neck, and face, predominantly up to one 
cm, some among which were necrotic and excoriated 
(Figure 1). There were three sites of clustered papules 
on the trunk, groin, and neck that resembled large, in-
filtrated plaques larger than two cm, at a glance mim-
icking cutaneous lymphoma (Figure 1, b, c). There 
were also older residual hyper- and hypopigmenta-
tions on the skin with prominent scarring. Excisional 
skin biopsy of one larger papule from the abdominal 
plaque was performed and was not morphologically 
or immunophenotypically different from the previ-
ous ones (Figure 2). Immunohistochemistry showed 
expression of CD 30 and the phenotypic markers of 
T-helper lymphocytes (CD 3+/-, CD4+) by neoplastic 
cells (Figure 2, c, d). Associated systemic malignant 
lymphoma was excluded based on examination find-
ings, normal laboratory tests, the absence of palpably 
enlarged lymph nodes, hepatosplenomegaly, and 
systemic symptoms followed with MSCT. Serology for 
HIV and EBV was performed and was positive for EBV 
EBNA, VCA IgG, and IgM, which could be associated 
with the exacerbation of LP. Topical corticosteroids 
and phototherapy were administered when needed 
in this 14-year period, and methotrexate in a lower 
dose was prescribed during the extensive general-
ized eruptions. All of the applied therapeutic modali-
ties led to a partial response. 
LP is a self-limiting disease for which many pa-
tients do not require specific treatment. Therapy 
should be directed at controlling symptoms in gen-
eralized eruptions or minimizing the frequency of 
recurrences, but none of the available treatment op-
tions disrupt the natural history of LP or reduce the 
risk of developing an associated lymphoma (6). Low-
dose methotrexate is the initial therapy of choice in 
patients with the extensive or symptomatic disease 
or disease involving cosmetically sensitive areas like 
the face or hands, which were the affected areas in 
our patient (6,7). There are no markers that can help 
predict the course of the disease in a given patient, 
although some indicators have been suggested (8,9). 
Because of this lack of markers that can help predict 
the course of the disease and occurrence of malig-
nant lymphoma, patients should remain in monitor-
ing for the rest of their life.
Figure 2. Lymphomatoid papulosis, type A. (a) Wedge-shaped infiltrate of predominantly clustered, large, atypical lympho-
cytes admixed with small lymphocytes, eosinophils, histiocytes, and neutrophil in the dermis (hematoxylin and eosin ×4). (b) 
Large, atypical cells arranged within collagen bundles (hematoxylin and eosin ×40). (c) Immunohistochemical staining for 
CD30 shows positive atypical cells in small clusters. (d) Staining for CD3 highlights the positive cells.
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